Rapamycin reduces renal hypoxia, interstitial in ammation and brosis in a rat model of unilateral ureteral obstruction
Currently chronic kidney disease (CKD) is a public health concern worldwide; however, the mechanism of kidney disease progression is still unclear. A hypothesis has been proposed that post-glomerular capillary injury or reduction in number of capillaries leads to chronic hypoxia of the tubular interstitium, which contributes to kidney disease progression and tissuebrosis [1, 2] . A number of growth factors can be a ected by hypoxia, and some of those growth factors, including transforming growth factor β1 (TGF-β1), play a role in interstitial metabolism [1, [3] [4] [5] . During periods of hypoxia, expression of vascular endothelial growth factor (VEGF) is markedly upregulated through a hypoxia-inducible factor (HIF)-1 dependent mechanism [6] . VEGF has two transmembrane tyrosine kinase receptors: Flk-1 (VEGF-R2) and Flt-1 (VEGF-R1) [7] . It has been found that both VEGF and TGF-β1 are involved in the pathogenesis of renal dysfunction and in the pathway mediating the progression to end-stage renal failure [8] .
Rapamycin is an immunosuppressive drug and its target, mammalian target of rapamycin (mTOR), is a downstream e ector of the phosphatidylinositol 3-kinase (PI3K) and Akt signaling pathways which regulate the protein translation process, interact with growth factors and their receptors and participate in cell cycle progression and membrane transport [9] . Rapamycin is an inhibitor of mTOR and it was found that it inhibited platelet-derived growth factor-induced proliferation and collagen synthesis in rat mesangial cells and alleviated tubulointerstitial in ammation and brosis in animal models [10] [11] [12] [13] . It is known that mTOR is implicated in the hypoxiainduced HIF-1 signaling pathway and a recent study shows that rapamycin can reduce stability and transforming activity of HIF-1α [14] . erefore, the e ects of rapamycin on renal hypoxia and chronic progressive nephropathy require further attention. e purpose of this study was to examine the e ects of rapamycin on renal hypoxia, interstitial in ammation and brosis, and expressions of TGF-β1, VEGF, Flk-1, and Flt-1 in a rat model of unilateral ureteral obstruction (UUO).
Methods

Animal preparation and experimental grouping
e ethics committee of Fudan University approved this study. Male Sprague-Dawley rats (n=36) weighing 170-206 g were purchased from the Experimental Animal Center of the School of Medicine, Fudan University. e animals were kept in a clean environment at 20± 2°C and provided with access to adequate food and water. e rats were randomly divided into three groups (n=12 in each group): sham operation, UUO and UUO treated with an intragastric gavage of rapamycin (0.2 mg/kg/d). e original concentration of rapamycin was 1 mg/ ml, which was diluted 1:10 with sterile tap water (Wyeth-Ayers Pharmaceuticals, Philadelphia, PA, USA). Rapamycin was given every morning starting from one day prior to UUO with the last dose given on the day the rats were sacri ced. e procedures of UUO are as follows: a er anesthetizing with 5% intraperitoneal sodium pentobarbitone (50 mg/kg), rats were xed in a supine position. Routine abdominal hair removal and skin disinfection were performed. An incision was cut on the le side, 1 cm away from the midline, and the abdominal cavity was opened to expose the le ureter. e upper one third of the ureter was dissected and then ligated using a No. 4 silk suture at two places, 0.5 cm apart. e ureter was then cut between the ligations to prevent retrograde infection. e surgery was then complete and the abdominal cavity was closed. e sham group only received laparotomy and dissection of the upper one third of the le ureter. Half of the animals in each group were sacri ced at day 3 a er surgery and the other half were sacri ced at day 7 a er surgery.
Sample collection e 24-hour urine samples of rats were collected one day prior to sacri ce using a metabolic cage to measure the 24-hour urine protein. Blood pressure was measured before the rats were anesthetized with intraperitoneal sodium pentobarbitone (50mg/kg). One and half hours prior to laparotomy, Hypoxyprobe-1 (Chemicon International, Dallas, TX, USA) 60 mg/kg was injected through the penile vein. Before nephrectomy was performed, a 3 mL venous blood sample was collected via the abdominal vein and centrifuged at 2000 rpm for 15 minutes. e serum was collected for measurement of serum creatinine (Scr), blood urea nitrogen (BUN), uric acid (UA), triglycerides and total cholesterol and measured with an ADVIA 1650 type automatic biochemical analyzer (Bayer, Tarrytown, NY, USA). Abdominal aortic cannulation was carried out and saline pre-chilled at 4°C was infused until the kidney turned a pale color. e renal pedicle was cut o and the kidney was removed. e capsule was rapidly removed while keeping the kidney on ice, and 2-3 mm thick transverse sections were made to prepare para n and frozen sections and to extract total RNA and tissue protein.
Hematoxylin and Eosin (HE) staining and Masson's trichrome staining
a thickness of 3 μm were prepared for staining. e visual elds (x200) were photographed and divided into 100 equal grids.
e number of the ber tissues with blue staining in each grid was calculated and scored 0 points for no interstitial brosis, 1 point for brosis extent <1/3, 2 points for brosis extent between 1/3 and 2/3, and 3 points for brosis extent >2/3. e score of interstitial brosis of each visual eld was the total score of the 100 grids. For the cortex and the medulla of each specimen, ve di erent visual elds were randomly-selected for examination and scoring.
Immunohistochemical staining
Formalin-xed and para n-embedded tissue samples were used for ED-1, Hypoxyprobe-1, TGF-β1, VEGF, Flk-1 (VEGF-R2), and Flt-1 (VEGF-R1) immunohistochemical staining and 4-micron sections were prepared. Immunohistochemical staining was achieved using primary antibodies including ED -1 (mouse monoclonal IgG, Serotec, Raleigh, NC, USA), Hypoxyprobe-1 (mouse anti-Hypoxyprobe-1, Chemicon), TGF-β 1 (rabbit polyclonal IgG, Santa Cruz, Dallas, TX, USA), VEGF (mouse monoclonal IgG, Santa Cruz), Flk-1 (VEGF-R2) (mouse monoclonal IgG, Santa Cruz), and Flt-1 (VEGF-R1) (rabbit polyclonal IgG, Santa Cruz) and secondary antibodies including Vectastain ABC kit, horse antimouse (purchased from Beijing Zhongshan Biological Technology, Beijing, China) and PowerVision two-step goat antirabbit IgG (Beijing Zhongshan). Because ED-1 is a marker of macrophages, the number of ED-1-positive cells re ects the degree of tissue in ammation. Five di erent non-overlapping high-power elds were selected from each of the cortex and medulla, and the number of ED-1 positive cells in those elds was counted. Pictures of Hypoxyprobe-1 immunohistochemical staining (x200) were taken and for each section, ve visual elds were selected from each of the cortex and medulla. For each positive target, the optical density was measured and the percentage of positive area was calculated. e amount of target antigen was calculated as the optical density of the positive target multiplied by the percentage of positive area.
Real-time polymerase chain reaction (RT-PCR)
Total RNA was extracted using TRIzol (Shanghai Sangon, Shanghai, China). A sample of 1 μg total RNA was incubated at 42°C for 30 min. e samples were heated at 95°C for 5 min to inactivate the DNase. e rst strand of cDNA was obtained by reversely transcribing RNA samples in a 20 μl reaction solution. e reaction system included 2 μl of template cDNA, 3 μl of MgCl2 (25 mM), 5 μl of 10xR bu er, 1 μl of dNTP (10mM), 1 μl of primers 1 and 2, 0.25 μl of TaqDNA synthase and nuclease-free water added to bring the nal volume to 50 μl. PCR thermal cycler (PTC-100, MJ Research, Paris, France) was used for the PCR reaction. Primer sequences and reaction conditions are presented in Table 1 . PCR products were separated by 1.2% agarose gel electrophoresis and stained with ethidium bromide staining. e band density of the PCR products on the agarose gel indicates the expression levels of target mRNA, which were calculated as a ratio with respect to the GAPDH band. Image acquisition under ultraviolet light and image analysis used a biological electrophoresis image analysis system (FR-200, Furi Technology, Shanghai, China).
Western blot
Tissue samples were homogenized on ice to prepare whole cell lysates and the protein concentration was determined using Bradford assay (Bio-Rad Laboratories, Hercules, CA, USA). An equal quantity of protein from each sample was loaded on the sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) and then transferred onto a nitrocellulose membrane (Millipore, Bedford, MA, USA).
e sample was blocked with 5% milk and incubated with one of the following primary antibodies: actin antibody (mouse monoclonal IgG, Santa Cruz), TGF-β 1 antibody (rabbit polyclonal IgG, Santa Cruz), VEGF antibody (mouse monoclonal IgG, Santa Cruz), Flk-1 antibody (VEGF-R2) (mouse monoclonal IgG, Santa Cruz), or Flt-1 antibody (VEGF-R1) (rabbit polyclonal IgG, Santa Cruz) at an optimized concentration (1:1000). e horseradish peroxidase-conjugated secondary antibodies (goat anti-mouse IgG (Shanghai Pufei Biotechnology, Shanghai, China) and goat anti-rabbit IgG (Shanghai Pufei Biotechnology) were then added into samples. e samples were washed three times between each addition of antibody. Enhanced chemiluminescent (ECL) substrates (Shanghai Pufei Biotechnology) were added and the images were developed on the Xray Film. Image acquisition and analyis under white light used a biological electrophoresis image analysis system (FR-200, Furi Technology) and the actin band was used as a reference.
Statistical analysis
Data are presented as mean ± standard deviation (SD). Continuous variables were compared by one-way analysis of variance (ANOVA). When statistical signi cance among groups was found, post hoc multiple comparisons of means were performed. e Tukey's test method for post hoc pairwise comparisons was applied when the equal variance assumption 
Results
Serum biochemical indices, 24-hour urine protein, and blood pressure
e serum creatinine, blood urea nitrogen (BUN), uric acid, cholesterol and triglyceride levels, 24-hour urine protein, and blood pressure of di erent groups are compared in Table 1 . Compared with the sham group, the serum creatinine levels were signi cantly increased in the UUO group at day 3 and day 7 and the BUN levels were signi cantly increased in the UUO group at day 7 (P < 0.001). Administration of rapamycin at 0.2 mg/kg/d signi cantly increased the serum creatinine levels and blood urea nitrogen at day 3 and day 7 compared with the sham group (P < 0.05).
Hypoxia of the kidney cortex and medulla
Fig . 1A and 1B shows the quantitative results of Hypoxyprobe-1 immunohistochemical staining. When compared with the sham operation, UUO caused an increase in hypoxia in the kidney cortex and medulla at day 3 and day 7 (P < 0.05). Administration of rapamycin signi cantly alleviated the hypoxia in both the cortex and medulla following UUO at day 3 and day 7 (P < 0.05; however, the level of hypoxia in the rapamycin group did not return to the level seen in the sham group (P < 0.05).
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Kidney cortex and medulla in ammation and interstitial brosis
e sham group had normal HE staining results at both day 3 and day 7 (data not shown). Fig. 1C shows the Hypoxyprobe-1 immunohistochemical staining results of UUO group and rapamycin treated group. In the UUO group, the glomeruli were normal, but di use dilation of the tubular lumens was observed at day 3. e tubular epithelial cells had incomplete brush borders and some of them (< 30%) were necrotic. Scattered inammatory cell in ltration was observed in the interstitium. e glomeruli in the UUO group remained normal at day 7, but the tubular lumens were di usively dilated, and the brush border of the tubular epithelial cells was incomplete. More than half of the tubular epithelial cells were necrotic. Vacuolar degeneration was observed, with aggravation of interstitial inammatory cell in ltration including more severe in ammatory cell in ltration in the medulla.
In the rapamycin group, the glomeruli remained normal and the tubular lumen was di usively dilated at day 3. e brush border of the tubular epithelial cells remained more intact and the tubular epithelial cell necrosis was reduced com- pared with the UUO group. Scattered in ammatory cell in ltration was still observed in the interstitium in the rapamycin group. e HE staining results of the rapamycin group at day 7 were not apparently di erent from that at day 3. e number of in ltrated ED-1 positive cells in the cortex and medulla was used to assess the degree of kidney cortex and medulla in ammation (Fig. 2) . As indicated by the increased number of in ltrated ED-1-positive cells in the kidney cortex and medulla, UUO caused an increase in the in ammatory reaction in the cortex and medulla at day 3 and day 7 compared with the sham group ( Fig. 2A and 2B , P < 0.05). Administration of rapamycin reduced the in ammatory reaction in the kidney cortex and medulla at day 3 and day 7 as indicated by the reduced number of in ltrated ED-1 positive cells ( Fig. 2A and 2B, P < 0.05). Furthermore, administration of rapamycin reduced the in ammatory reaction in the kidney cortex and medulla to a level that was not signi cantly di erent from that in the sham group at day 7 (Fig. 2B ). e mRNA expression levels of type III collagen were used to re ect the degree of interstitial brosis. UUO increased the type III collagen mRNA levels in the kidney tissues at day 3 and day 7 compared with the sham group (Fig. 3 , P < 0.05). Administration of rapamycin failed to signi cantly reduce the elevated type III collagen mRNA levels induced by UUO at day 3 or day 7 (Fig. 3) . e interstitial brosis scores were compared among groups (Fig.  4) . e interstitial brosis scores of the kidney cortex and medulla were elevated in the UUO group compared with the sham group (Fig. 4A and 4B , P < 0.05). e interstitial brosis scores were signi cantly reduced by rapamycin at day 3 and day 7 ( Fig. 4A and 4B , P < 0.05), but the interstitial brosis scores of the rapamycin group were still higher than those of the sham group at day 3 and day 7 ( Fig. 4A and 4B , P < 0.05). Figure 5 shows the expression of TGF-β1 mRNA and protein in the three groups. e expression levels of TGF-β1 mRNA and protein were elevated in the UUO group compared with the sham group at day 3 and day 7 ( Fig. 5A and 5B, P < 0.05). At day 3 (Fig. 5A) , administration of rapamycin lowered the expression of TGF-β1 mRNA and protein compared with the UUO group (P < 0.05). e level of TGF-β1 mRNA expression in the rapamycin group was reduced to a level that was even lower than that in the sham group (P < 0.05), and the level of TGF-β1 protein expression in the rapamycin group was reduced to a level that was not signi cantly di erent from that in the sham group. At day 7 (Fig. 5B) , administration of rapamycin lowered the expression of TGF-β1 mRNA and protein compared with the UUO group (P < 0.05), but the lowered levels of TGF-β1 mRNA and protein expression were still higher than those in the sham group (P < 0.05). Figure 6 shows that expression of VEGF mRNA and protein were increased in the UUO group compared with the sham group at day 3 and day 7 ( Fig. 6A and 6B , P < 0.05). At day 3, administration of rapamycin lowered the levels of VEGF mRNA and protein compared with the UUO group (P < 0.05), with no signi cant di erence found between the rapamycin and the sham groups (Fig. 6A) . At day 7, administration of rapamycin did not change the expression of VEGF mRNA or protein signi cantly compared with the UUO group (Fig.  6B) .
Expression of TGF-β1 mRNA and protein
Expression of VEGF mRNA and protein
Expression of Flk-1 and Flt-1 mRNA and protein
e expression levels of Flk-1 and Flt-1 mRNA and protein are shown in Figure 7 . Expression of Flk-1 mRNA and protein were elevated in the UUO group compared with the sham group at day 3 ( Fig. 7A, P < 0.05) . At day 7 (Fig. 7B) , the Flk-1 mRNA levels in the UUO group returned to a level that was C.
FIGURE 5. Expression of TGF-β1 mRNA and protein by group at (A) day 3 and (B) day 7 (n=6 per group). Data were shown as mean ± standard deviation. One-way ANOVA followed by Tukey's test for post hoc tests were performed. *Indicates a signi cant di erence between the treatment and UUO groups, P < 0.05. †Indicates a signi cant di erence between the treatment and sham groups, P < 0.05. (C) Western blot analyses of TGF-β1 proteins (1= UUO group; 2= UUO+ rapamycin group). Actin was used as a control.
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FIGURE 6. Expression of VEGF mRNA and protein by group at (A) day 3 and (B) day 7 (n=6 per group). Data were shown as mean ± standard deviation. One-way analysis of variance followed by either Tukey's or Dunnett's T3 posthoc tests was performed. *Indicates a signi cant di erence between the treatment and UUO groups, P < 0.05. †Indicates a signi cant di erence between the treatment and sham groups, P < 0.05. (C) Western blot analyses of VEGF proteins (1= UUO group; 2= UUO+ rapamycin group). Actin was used as a control.
not signi cantly di erent from that in the sham group, but the Flk-1 protein levels in the UUO group were still higher than that in the sham group (P < 0.05). At day 3 and day 7, administration of rapamycin signi cantly increased the levels of Flk-1 mRNA and protein compared with the UUO and sham group, (P < 0.05). e only exception to this was that the increase in Flk-1 mRNA levels of the rapamycin group compared with the UUO group at day 3 was not signi cant (Fig. 7A) . Compared with the sham group, UUO increased the expression levels of Flt-1 mRNA and protein at day 3 and day 7 (P < 0.05). At day 3 and day 7, administration of rapamycin reduced the levels of Flt-1 mRNA and protein compared with the UUO group (P < 0.05). e expression levels of Flk-1 mRNA and protein in the rapamycin group were still signicantly higher than those in the sham group ( Fig. 7A and 7B ).
Discussion
In this study, UUO induced in ltration of in ammatory cells in the interstitium as well as interstitial brosis, as indicated by the HE staining, the increased number of in ltrated ED-1 positive cells and the upregulated type III collagen mRNA levels. Hypoxyprobe-1 immunohistochemical staining results indicate that UUO caused an increased degree of hypoxia in the kidney cortex and medulla at day 3 and day 7, accompanied by elevated TGF-β1, VEGF, Flk-1, and Flt-1 mRNA and protein expressions. Administration of rapamycin alleviated the UUOinduced renal hypoxia, in ltration of in ammatory cells and tubulointerstitial brosis, and it down-regulated the UUOinduced elevated expression levels of TGF-β1 and Flt-1 mRNA and protein (P<0.05). Compared with the UUO group, the rapamycin group showed decreased VEGF mRNA and protein expression at day 3, and increased Flk-1 mRNA and protein expression at day 7 (P < 0.05). Rapamycin can inhibit lymphocyte proliferation and di erentiation, tumor angiogenesis, replication of cytomegalovirus, growth factor-mediated proliferation of vascular smooth muscle and endothelial cells and broblast proliferation [15] . It may also inhibit proliferation and collagen synthesis induced by platelet-derived growth factor in rat mesangial cells [10, 11] . Our study found that rapamycin can alleviate UUO-induced renal hypoxia and brosis, which may be related to its anti-in ammatory and anti-proliferative e ects. In addition, the PI3K signaling pathway is involved in the HIF-1 signaling pathway, and the downstream e ector of the PI3K is mTOR [9] , which can be inhibited by rapamycin. is may be another mechanism by which rapamycin alleviates renal hypoxia. In a recent study conducted by Tamura et al., mTOR/ (phosphorylation of ribosomal protein S6 kinase 1) S6K/HIF-1 α signaling was found to be activated by hypoxia in ovarian clear cell adenocarcinoma cells cultured in vitro [16] . As an inhibitor of mTOR, rapamycin decreased the level of HIF-1 α and blocked the transcriptional regulator of mTOR, S6K [16] . In a mouse model of B-cell lymphoma xenogra , mTOR inhibitors mediated tumor cell apoptosis and it was found that the apoptotic e ects were caused by the reduced VEGF protein expression and the downregulation of angiogenesis [17] . In a rat kidney model of chronic allogra dysfunction, another mTOR inhibitor, rapamycin attenuated tubulointerstitial damage, glomerulosclerosis, leucocyte accumulation and vasculopathy, which was associated with diminished expression of VEGF and VEGF receptor mRNA and protein [18] . In podocytes, endothelial and mesangial cells cultured in vitro, rapamycin not only reduced VEGF production in podocytes but also inhibited VEGF-induced proliferation of podocytes, endothelial and mesangial cells [18] . e speci c mechanism by which rapamycin alleviates renal hypoxia still needs to be further explored.
Compared with the sham group, rapamycin signi cantly downregulated the VEGF mRNA and protein expression levels at day 3 (p <0.05), but not at day 7. is early-stage decline might be the result of mTOR inhibition and improved renal hypoxia resulting in decreased HIF-1 accumulation. e relative increase at a later stage might be explained by the overall increase in the VEGF production caused by alleviation of renal tubular epithelial cell injury. As for the VEGF receptors, rapamycin down-regulated the elevated expression levels of Flt-1 mRNA and protein induced by UUO at day 3 and day 7, but it increased Flk-1 mRNA at day 7 and protein expression at day 3 and day 7. e role of these changes in the VEGF and its receptors in UUO-induced renal injury is still unknown, and further study is warranted.
In early-stage diabetic nephropathy, the levels of VEGF and its receptors are elevated, which promotes the hypertrophy of glomeruli and tubules and the early progression of nephropathy [16, 17] . e VEGF suppression at that time may improve glomerular hyper ltration, proteinuria and glomerular hypertrophy [19, 20] . Since rapamycin can inhibit the expression of VEGF, its potential e ects delaying the progression of diabetic nephropathy requires further attention. e main adverse e ects of rapamycin are thrombocytopenia and hyperlipidemia in a dose-dependent manner [21] .
Our RT-PCR data demonstrates that rapamycin (0.2 mg/ kg/day) signi cantly lowered the expression of TGF-β1 mRNA. In a previous study by Wu et al., rapamycin treatment, at a dose of 1 mg/kg/day, did not reduce TGF-beta mRNA expression at day 7 a er UUO operation as assessed by Northern blot analysis [12] . One explanation for this discrepancy in results may be the sensitivity and accuracy of the experimental methods used. As RT-PCR is more sensitive than Northern blot for detection of mRNA levels [22] , smaller di erences in expression are more likely to be detected by RT-PCR. Furthermore, over-saturation of signal will lead to an overestimation of the expression level in a Northern blot analysis.
is study had some limitations. First, whether rapamycin plays a role in the regulation of HIF-1 alpha and m-TOR in this model was not addressed. Since HIF-1alpha is a key regulator of hypoxia and VEGF expression, future studies should address this topic. Platelet changes were not measured, but the cholesterol elevation caused by rapamycin at day 3 returned to a level not signi cantly di erent from that in the sham group at day 7. At the same time, the triglyceride levels in the rapamycin group did not change signi cantly compared to the sham group. e rapamycin dose (0.2 mg/kg/d) in our study was low, and that might be the reason that the blood lipid changes were not salient.
In summary, rapamycin shows bene cial e ects in improving UUO-induced renal hypoxia, in ammation, and tubulointerstitial brosis in rats. It alleviated the UUO-induced renal hypoxia, in ltration of in ammatory cells and tubulointerstitial brosis at day 3 and day 7. It also altered the elevated mRNA and protein expressions of a series of growth factors and receptors a er UUO including TGF-β1, VEGF, Flt-1, and Flk-1.
ese nding suggest that rapamycin might have the potential as a protective or therapeutic agent for progressive renal brosis in human.
